TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic ...
WILMINGTON, Del.--(BUSINESS WIRE)--Jun 12, 2026-- AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic …